The emergence of the epidermal growth factor receptor (EGFR) C797S mutation in the absence of T790M represents a common mechanism of acquired resistance to first-line osimertinib in non-small cell lung cancer (NSCLC), posing a significant clinical challenge. Here, EGFR is linked to non-small cell lung carcinoma.